Entrada Therapeutics · 12 hours ago
Manager, Early Innovation & Scientific Strategy
Boston, MA
Full-time
Hybrid
Mid Level
$152K/yr - $190K/yr
3+ years expEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines. The Manager, Early Innovation & Scientific Strategy will play a critical role in shaping Entrada’s early-stage pipeline by supporting strategic assessment of new indications and translating emerging scientific data into actionable development recommendations.
BiotechnologyEmergency MedicineGeneticsHealth CareMedical
Responsibilities
Conduct structured evaluations of potential new indications, including disease biology, patient populations, unmet needs, standard of care, competitive landscape, and therapeutic rationale
Develop indication scoring frameworks or decision models to inform program prioritization with R&D and business leadership
Translate scientific concepts into clear strategic implications for pipeline fit and development paths
Identify, engage, and maintain relationships with Key Opinion Leaders (KOLs), academic experts, and clinical investigators to inform program hypotheses and development strategy
Prepare background materials, discussion guides, and summaries from KOL interactions to guide internal strategic discussions
Monitor evolving scientific and clinical trends relevant to target indications or modalities
Analyze internal experimental data, translational findings, and preclinical results to identify development opportunities, gaps, or next-step experiments
Develop clear, actionable recommendations for program progression, experimental design, or alliance strategy
Support creation of strategic narratives, including target product profiles (TPPs), development roadmaps, and go/no-go frameworks
Work closely with Discovery Research, Program Management, and Business Development to develop integrated early program plans
Support preparation of materials for internal governance, external collaborators, and Executive Leadership
Ensure early strategy work is aligned with broader company goals and partnership commitments
Qualification
Required
Advanced degree in life sciences (PhD, MS, or equivalent) required, biology & physiology (or similar) focus preferred
3+ years of experience in biotech/pharma in roles such as program strategy, competitive intelligence, translational science, or management consulting with a life sciences focus
Strong scientific literacy with the ability to interpret preclinical and translational data
Excellent communication skills and ability to synthesize complex information into clear, structured recommendations
Ability to work independently, manage multiple workstreams, and collaborate effectively in a cross-functional environment
Preferred
Experience interacting with external experts or KOLs is strongly preferred
Experience conducting indication assessments and/or evaluating disease biology
Benefits
Comprehensive health, dental and vision coverage
Life and disability insurance
401(k) match
Paid, gender-inclusive parental leave
Holistic support for your health and well-being
Education reimbursement
Discretionary time off
Commuting benefits aligned to your working model
Company
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
51-200 employees
H1B Sponsorship
Entrada Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (7)
2024 (14)
2023 (4)
2022 (6)
2021 (1)
2020 (1)
Funding
Current Stage
Public CompanyTotal Funding
$301.6MKey Investors
Wellington Management
2024-06-24Post Ipo Equity· $100M
2022-12-08Post Ipo Equity· $26M
2021-10-29IPO
Leadership Team
Dipal Doshi
Chief Executive Officer
Leo Qian
Co-Founder
Recent News
2025-12-17
2025-11-22
Company data provided by crunchbase